MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/120/0.1/21.03.25 | Real-time Bid/Ask 11:59:43 03/06/2024 BST | ||
| 0.23 EUR / 0.35 EUR | +32.42% |
|
| 1 month | +25.14% | ||
| 3 months | +0.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.219 | -8.75% |
| 30/05/24 | 0.24 | +1.69% |
| 29/05/24 | 0.236 | +22.92% |
| 28/05/24 | 0.192 | 0.00% |
| 27/05/24 | 0.192 | +4.92% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:59 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB8GSD |
| ISIN | DE000MB8GSD8 |
| Date issued | 07/07/2023 |
| Strike | 120 $ |
| Maturity | 21/03/2025 (292 Days) |
| Parity | 10 : 1 |
| Emission price | 0.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.75 € |
|---|---|
| Lowest since issue | 0.131 € |
| Spread | 0.12 € |
| Spread % | 34.29% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.89
USD
Average target price
96.55
USD
Spread / Average Target
+11.12%
- Stock Market
- Warrants
- Warrant
